Study guide
3.1 Receptor Pharmacology & Autonomic Nervous System
PSI Equivalence Examination Third Country Qualification Recognition
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & TCQR Framework
1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment
2 Chapter 2: Pharmaceutical Calculations
2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions
3 Chapter 3: Pharmacology & Applied Pharmacokinetics
3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
4 Chapter 4: Basic Science & Pharmaceutics
4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence
5 Chapter 5: Pharmacy Practice & Dispensing Workflow
5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services
6 Chapter 6: Irish Pharmacy Law & Professional Ethics
6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct
7 Chapter 7: Clinical Therapeutics & Disease State Management
7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care
8 Chapter 8: OSCE & Practical Clinical Communication Skills
8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement
3.1 Receptor Pharmacology & Autonomic Nervous System
Key Takeaways Explain This Topic AI
Full agonists stabilize active receptor conformations to produce a maximal effect (Emax), whereas competitive antagonists bind reversibly without receptor activation, producing a parallel rightward shift in the log concentration-response curve without altering Emax.
Partial agonists possess intrinsic activity between 0 and 1; in the absence of a full agonist they act as weak agonists, but in the presence of a full agonist they function as competitive antagonists by competing for receptor binding.
Receptor affinity is quantified by the dissociation constant (Kd), while drug potency is measured by EC50 (the concentration yielding 50% of maximal response); lower Kd and EC50 values indicate higher affinity and potency, respectively.
The autonomic nervous system utilizes dual neurotransmission: sympathetic postganglionic neurons predominantly release norepinephrine acting on α- and β-adrenoceptors, whereas parasympathetic postganglionic neurons release acetylcholine acting on M1–M3 muscarinic receptors.
Anticholinergic toxicity presents as a classic clinical syndrome ('dry as a bone, blind as a bat, red as a beet, hot as a hare, mad as a hatter, and bowel/bladder lose their tone'), manageable with supportive care and the acetylcholinesterase inhibitor physostigmine.
Last updated: July 2026
3.1 Receptor Pharmacology & Autonomic Nervous System
Quick Reference: Receptor pharmacology defines how drug molecules interact with biological targets to produce therapeutic or toxic responses. Understanding ligand-receptor kinetics, dose-response relationships, and autonomic nervous system (ANS) neurotransmission is essential for predicting pharmacological responses and managing clinical toxicity.
Pharmacodynamics describes what a drug does to the body, focusing on receptor binding, signal transduction, and physiological response. The autonomic nervous system provides the classic anatomical framework for studying receptor subtypes, agonist activity, and antagonist blockade.
Principles of Receptor Interactions & Pharmacodynamics
Drugs exert pharmacological effects by interacting with macromolecular targets, primarily cell-surface or intracellular receptors, ion channels, enzymes, and carrier proteins. The interaction between a drug ( D D D ) and a receptor ( R R R ) follows reversible mass-action kinetics: D + R ⇌ D R → Effect D + R \rightleftharpoons DR \rightarrow \text{Effect} D + R ⇌ D R → Effect
Quantitative Parameters
Affinity ( K d K_d K d ): The equilibrium dissociation constant, defined as the drug concentration at which 50% of total receptors are occupied. K d K_d K d is inversely proportional to affinity; a lower K d K_d K d value indicates higher binding affinity.
Potency ( E C 50 EC_{50} E C 50 ): The molar concentration of a drug required to produce 50% of its maximal physiological effect. Potency depends on both affinity ( K d K_d K d ) and tissue coupling efficiency.
Efficacy ( E m a x E_{max} E ma x ): The maximum response obtainable by a drug when all available receptors are occupied or maximum intracellular signaling is achieved. Efficacy reflects intrinsic activity ( α \alpha α ).
Agonists, Partial Agonists, and Antagonists
Ligands are classified based on their intrinsic activity ( α \alpha α ), which describes their capacity to activate a receptor upon binding.
Ligand Classifications
Full Agonists ( α = 1 \alpha = 1 α = 1 ): Bind to and fully stabilize the active receptor conformation ( R ∗ R^* R ∗ ), eliciting the maximal biological response ( E m a x E_{max} E ma x ) achievable by the tissue.
Partial Agonists ( 0 < α < 1 0 < \alpha < 1 0 < α < 1 ): Bind to receptors but induce submaximal stabilization of R ∗ R^* R ∗ , resulting in a ceiling effect ( E m a x E_{max} E ma x lower than full agonists) even at 100% receptor occupancy.
Clinical Significance: In the absence of a full agonist, partial agonists act as agonists. In the presence of a full agonist, partial agonists act as competitive antagonists by occupying receptors and lowering the overall physiological response (e.g., buprenorphine at μ \mu μ -opioid receptors, pindolol at β \beta β -adrenoceptors).
Competitive Antagonists ( α = 0 \alpha = 0 α = 0 ): Bind reversibly to the active site of the receptor without inducing activation. They prevent agonist binding.
Dose-Response Effect: Causes a parallel rightward shift of the log concentration-response curve (increases E C 50 EC_{50} E C 50 ) without reducing E m a x E_{max} E ma x . The antagonism is surmountable by increasing agonist concentration.
Non-Competitive & Irreversible Antagonists: Bind either irreversibly via covalent bonds to the active site (e.g., phenoxybenzamine at α \alpha α -receptors) or allosterically to a distinct site.
Dose-Response Effect: Decreases E m a x E_{max} E ma x (depresses maximal response) and cannot be surmounted by adding more agonist. E C 50 EC_{50} E C 50 may remain unchanged.
Inverse Agonists ( α < 0 \alpha < 0 α < 0 ): Bind preferentially to the inactive receptor state ( R R R ), suppressing constitutive (basal) receptor activity in systems with spontaneous signaling (e.g., GABA-A receptor inverse agonists).
Therapeutic Index & Margin of Safety
The Therapeutic Index (TI) quantifies drug safety: Therapeutic Index (TI) = T D 50 E D 50 or L D 50 E D 50 \text{Therapeutic Index (TI)} = \frac{TD_{50}}{ED_{50}} \quad \text{or} \quad \frac{LD_{50}}{ED_{50}} Therapeutic Index (TI) = E D 50 T D 50 or E D 50 L D 50
Where T D 50 TD_{50} T D 50 is the median toxic dose, L D 50 LD_{50} L D 50 is the median lethal dose, and E D 50 ED_{50} E D 50 is the median effective dose. A wider TI indicates a safer drug profile.
The Autonomic Nervous System (ANS): Organization & Neurotransmitters
The ANS regulates involuntary visceral functions through two main efferent divisions: the Sympathetic Nervous System (SNS) (thoracolumbar origin; fight-or-flight) and the Parasympathetic Nervous System (PNS) (craniosacral origin; rest-and-digest).
Neurotransmission Summary
Preganglionic Neurons (All ANS): Release Acetylcholine (ACh) acting on Nicotinic ( N N N_N N N ) ionotropic receptors at autonomic ganglia.
Parasympathetic Postganglionic Neurons: Release ACh acting on Muscarinic ( M 1 − M 5 M_1-M_5 M 1 − M 5 ) metabotropic receptors on target tissues.
Sympathetic Postganglionic Neurons: Predominantly release Norepinephrine (NE) acting on α \alpha α - and β \beta β -adrenoceptors . Exceptions include sweat glands (release ACh acting on M 3 M_3 M 3 ) and renal vascular smooth muscle (release Dopamine acting on D 1 D_1 D 1 ).
Adrenal Medulla: Chromaffin cells function as modified postganglionic sympathetic neurons, releasing Epinephrine (80%) and Norepinephrine (20%) directly into systemic circulation.
Autonomic Receptor Subtypes & Signal Transduction
Receptor Subtype Primary Tissue Location G-Protein Coupling & Second Messenger Physiological Effect
α 1 \alpha_1 α 1 Adrenoceptor Vascular smooth muscle, pupillary dilator muscle, internal urethral sphincter G q → ↑ IP 3 / DAG , ↑ Ca 2 + G_q \rightarrow \uparrow \text{IP}_3 / \text{DAG}, \uparrow \text{Ca}^{2+} G q →↑ IP 3 / DAG , ↑ Ca 2 + Vasoconstriction, mydriasis, urinary sphincter contraction
α 2 \alpha_2 α 2 Adrenoceptor Presynaptic adrenergic nerve terminals, CNS brainstem (vasomotor center), pancreatic islets G i → ↓ cAMP G_i \rightarrow \downarrow \text{cAMP} G i →↓ cAMP Presynaptic auto-inhibition (decreases NE release), reduces central sympathetic outflow, decreases insulin secretion
β 1 \beta_1 β 1 Adrenoceptor Heart (SA node, AV node, myocardium), Juxtaglomerular cells (kidney) G s → ↑ cAMP G_s \rightarrow \uparrow \text{cAMP} G s →↑ cAMP Positive chronotropy (heart rate), positive inotropy (contractility), positive dromotropy (conduction speed), increases renin release
β 2 \beta_2 β 2 Adrenoceptor Bronchial smooth muscle, skeletal muscle vascular beds, uterine smooth muscle, liver G s → ↑ cAMP G_s \rightarrow \uparrow \text{cAMP} G s →↑ cAMP Bronchodilation, vasodilation in skeletal muscle, uterine relaxation (tocolysis), glycogenolysis
β 3 \beta_3 β 3 Adrenoceptor Adipose tissue, detrusor muscle of bladder G s → ↑ cAMP G_s \rightarrow \uparrow \text{cAMP} G s →↑ cAMP Lipolysis, detrusor relaxation (promotes urine storage)
M 1 M_1 M 1 Muscarinic CNS, gastric parietal cells, autonomic ganglia G q → ↑ IP 3 / DAG , ↑ Ca 2 + G_q \rightarrow \uparrow \text{IP}_3 / \text{DAG}, \uparrow \text{Ca}^{2+} G q →↑ IP 3 / DAG , ↑ Ca 2 + CNS excitation, increased gastric acid secretion
M 2 M_2 M 2 Muscarinic Heart (SA node, AV node, atrium) G i → ↓ cAMP , ↑ K + current G_i \rightarrow \downarrow \text{cAMP}, \uparrow \text{K}^+ \text{current} G i →↓ cAMP , ↑ K + current Negative chronotropy (decreases HR), negative dromotropy (decreases AV conduction)
M 3 M_3 M 3 Muscarinic Smooth muscle (airways, GI tract, bladder detrusor), exocrine glands, vascular endothelium G q → ↑ IP 3 / DAG , ↑ Ca 2 + G_q \rightarrow \uparrow \text{IP}_3 / \text{DAG}, \uparrow \text{Ca}^{2+} G q →↑ IP 3 / DAG , ↑ Ca 2 + Bronchoconstriction, increased GI motility, detrusor contraction (micturition), profuse sweating/salivation, endothelial nitric oxide (NO) vasodilation
- Sympathomimetic & Parasympathomimetic Pharmacology
- Sympathomimetics
Direct-Acting Agonists:
Adrenaline (Epinephrine): Non-selective α 1 , α 2 , β 1 , β 2 \alpha_1, \alpha_2, \beta_1, \beta_2 α 1 , α 2 , β 1 , β 2 agonist. First-line for anaphylaxis (1:1000 IM, 0.5mg in adults), severe croup, and cardiac arrest.
Noradrenaline (Norepinephrine): Potent α 1 , α 2 , β 1 \alpha_1, \alpha_2, \beta_1 α 1 , α 2 , β 1 agonist with minimal β 2 \beta_2 β 2 activity. First-line vasopressor for septic shock to increase systemic vascular resistance (SVR).
Salbutamol (Albuterol) & Salmeterol: Selective β 2 \beta_2 β 2 agonists used as short-acting (SABA) and long-acting (LABA) bronchodilators in asthma and COPD.
Phenylephrine: Selective α 1 \alpha_1 α 1 agonist used as a nasal decongestant and vasopressor for spinal anesthesia hypotension.
Clonidine & Dexmedetomidine: Central α 2 \alpha_2 α 2 agonists reducing sympathetic tone, used in hypertension, ADHD, opioid withdrawal, and ICU sedation.
Indirect-Acting Sympathomimetics:
Amphetamine & Tyramine: Displace stored norepinephrine from presynaptic vesicles into the synaptic cleft.
Cocaine & Atomoxetine: Inhibit the norepinephrine transporter (NET), blocking NE reuptake.
Parasympathomimetics
Direct Muscarinic Agonists:
Bethanechol: M 3 M_3 M 3 -selective agonist used for non-obstructive urinary retention and neurogenic bladder.
Pilocarpine: M 3 M_3 M 3 agonist used topically for open-angle glaucoma (induces miosis and trabecular meshwork drainage) and orally for xerostomia (Sjögren's syndrome).
Reversible Acetylcholinesterase (AChE) Inhibitors:
Neostigmine & Pyridostigmine: Quaternary ammonium compounds that increase synaptic ACh; used in Myasthenia Gravis and reversal of non-depolarizing neuromuscular blockade.
Donepezil, Galantamine, Rivastigmine: CNS-penetrating AChE inhibitors used to manage mild-to-moderate Alzheimer's dementia.
Edrophonium: Short-acting AChE inhibitor historically used in the Tensilon test for Myasthenia Gravis diagnosis.
Irreversible Organophosphates & Toxicology:
Organophosphate insecticides (e.g., malathion, parathion) and nerve agents (sarin) irreversibly phosphorylate the AChE esteratic site.
Presentation: Cholinergic crisis— DUMBBELSS (Diarrhea, Urination, Miosis, Bronchospasm/Bradycardia, Emesis, Lacrimation, Salivation, Sweating) plus muscle fasciculations and paralysis.
Treatment: Atropine (blocks muscarinic manifestations) + Pralidoxime (2-PAM) (reactivates AChE by cleaving organophosphate-enzyme bond before 'aging' occurs).
Anticholinergic Agents & Clinical Toxicology
Muscarinic receptor antagonists competitively block ACh actions at parasympathetic neuroeffector junctions.
Key Muscarinic Antagonists
Atropine: Tertiary amine muscarinic antagonist; used for severe symptomatic bradycardia, organophosphate poisoning, and pre-operative inhibition of secretions.
Hyoscine (Scopolamine): Crosses blood-brain barrier; used as a transdermal patch for motion sickness and end-of-life respiratory secretions ("death rattle").
Ipratropium & Tiotropium: Quaternary ammonium SAMA and LAMA inhalers used in COPD and acute severe asthma; minimal systemic absorption.
Oxybutynin, Solifenacin, Tolterodine: M 3 M_3 M 3 -selective antagonists used for overactive bladder and urge incontinence.
Anticholinergic Toxidrome
Excessive anticholinergic blockade (e.g., atropine, tricyclic antidepressants, diphenhydramine overdose) presents with the classic clinical mnemonic:
- "Dry as a bone" (Anhidrosis, dry mucous membranes)
- "Blind as a bat" (Mydriasis, loss of accommodation/cycloplegia)
- "Red as a beet" (Cutaneous vasodilation/flushing)
- "Hot as a hare" (Hyperthermia due to loss of sweating)
- "Mad as a hatter" (Delirium, hallucinations, agitation)
- Bowel and bladder lose their tone (Paralytic ileus, urinary retention)
Management: Supportive care, cooling, urinary catheterization. In severe central toxicity, administer the tertiary AChE inhibitor Physostigmine .